HTG MOLECULAR DIAGNOSTICS, INC Quarterly Debt-to-equity in % from Q3 2015 to Q1 2023

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Htg Molecular Diagnostics, Inc quarterly Debt-to-equity history and growth rate from Q3 2015 to Q1 2023.
  • Htg Molecular Diagnostics, Inc Debt-to-equity for the quarter ending March 31, 2023 was 410 %, a 197% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q1 2023 410 +272 +197% Mar 31, 2023
Q4 2022 250 +121 +93.3% Dec 31, 2022
Q3 2022 233 +111 +90.7% Sep 30, 2022
Q2 2022 175 +53.4 +44.1% Jun 30, 2022
Q1 2022 138 +14.5 +11.7% Mar 31, 2022
Q4 2021 129 +14.5 +12.7% Dec 31, 2021
Q3 2021 122 +20.3 +19.9% Sep 30, 2021
Q2 2021 121 +29.8 +32.7% Jun 30, 2021
Q1 2021 123 +21.2 +20.8% Mar 31, 2021
Q4 2020 115 +4.79 +4.35% Dec 31, 2020
Q3 2020 102 -14.3 -12.3% Sep 30, 2020
Q2 2020 91.3 -32.6 -26.3% Jun 30, 2020
Q1 2020 102 +2.21 +2.21% Mar 31, 2020
Q4 2019 110 +22.9 +26.2% Dec 31, 2019
Q3 2019 116 -0.16 -0.14% Sep 30, 2019
Q2 2019 124 -54.5 -30.6% Jun 30, 2019
Q1 2019 99.8 -310 -75.7% Mar 31, 2019
Q4 2018 87.2 +533 Dec 31, 2018
Q3 2018 116 +511 Sep 30, 2018
Q2 2018 178 +636 Jun 30, 2018
Q1 2018 410 +1.08K Mar 31, 2018
Q4 2017 -446 -2.02K -128% Dec 31, 2017
Q3 2017 -395 -753 -210% Sep 30, 2017
Q2 2017 -458 -646 -343% Jun 30, 2017
Q1 2017 -674 -798 -646% Mar 31, 2017
Q4 2016 1.57K +2.75K Dec 31, 2016
Q3 2016 358 +455 Sep 30, 2016
Q2 2016 188 Jun 30, 2016
Q1 2016 124 Mar 31, 2016
Q4 2015 -1.18K Dec 31, 2015
Q3 2015 -97.3 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.